Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 7/20 | 0.75 |
| ▸ | CA1 | P00915 | 1/20 | 0.75 |
| ▸ | CES2 | O00748 | 4/20 | 0.70 |
| ▸ | CES1 | P23141 | 4/20 | 0.70 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanoic Acid SCHEMBL1316022 | 1.00 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL29620682 | 1.00 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Dodecanoate SCHEMBL17476381 | 1.00 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL3765071 | 1.00 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL1360333 | 1.00 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Palmitic Acid SCHEMBL1628227 | 1.00 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Arachidic Acid SCHEMBL25286669 | 0.97 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL25379316 | 0.97 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Decanoic Acid SCHEMBL23291022 | 0.97 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Nonanoate SCHEMBL25268146 | 0.97 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-8425880-B1 | Metal-containing materials for treatment of bacterial conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-23 | — | — | US | disclosed |
| US-20130095184-A1 | Metal-Containing Materials for Treatment of Bacterial Conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009014781-A2 | METAL-CONTAINING MATERIALS FOR TREATMENT OF BACTERIAL CONDITIONS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2009-01-29 | — | — | WO | disclosed |
| US-20080050452-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-28 | — | — | US | disclosed |
| US-20080044491-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-21 | — | — | US | disclosed |
| US-20080014278-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| US-20080014247-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| WO-2008005705-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | SELENOI, TST, SCLY | FABP3 1220/4885CA1 3748/4885CES2 1370/4885 |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | SELENOI, TST, GSS | FABP3 1166/4885CA1 4100/4885CES2 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.